Search

Your search keyword '"Szymonifka, Jackie"' showing total 12 results
Start Over Author "Szymonifka, Jackie" Publication Year Range Last 3 years
12 results on '"Szymonifka, Jackie"'

1. Supplementary Table 1 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1

Author

Heuck, Christoph J., primary, Szymonifka, Jackie, primary, Hansen, Emily, primary, Shaughnessy, John D., primary, Usmani, Saad Z., primary, van Rhee, Frits, primary, Anaissie, Elias, primary, Nair, Bijay, primary, Waheed, Sarah, primary, Alsayed, Yazan, primary, Petty, Nathan, primary, Bailey, Clyde, primary, Epstein, Joshua, primary, Hoering, Antje, primary, Crowley, John, primary, and Barlogie, Bart, primary

Published
2023
Full Text
View/download PDF

2. Supplementary Figure 1 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1

Author

Heuck, Christoph J., primary, Szymonifka, Jackie, primary, Hansen, Emily, primary, Shaughnessy, John D., primary, Usmani, Saad Z., primary, van Rhee, Frits, primary, Anaissie, Elias, primary, Nair, Bijay, primary, Waheed, Sarah, primary, Alsayed, Yazan, primary, Petty, Nathan, primary, Bailey, Clyde, primary, Epstein, Joshua, primary, Hoering, Antje, primary, Crowley, John, primary, and Barlogie, Bart, primary

Published
2023
Full Text
View/download PDF

4. Supplementary Figure 2 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1

Author

Heuck, Christoph J., primary, Szymonifka, Jackie, primary, Hansen, Emily, primary, Shaughnessy, John D., primary, Usmani, Saad Z., primary, van Rhee, Frits, primary, Anaissie, Elias, primary, Nair, Bijay, primary, Waheed, Sarah, primary, Alsayed, Yazan, primary, Petty, Nathan, primary, Bailey, Clyde, primary, Epstein, Joshua, primary, Hoering, Antje, primary, Crowley, John, primary, and Barlogie, Bart, primary

Published
2023
Full Text
View/download PDF

5. Supplementary Figure 3 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1

Author

Heuck, Christoph J., primary, Szymonifka, Jackie, primary, Hansen, Emily, primary, Shaughnessy, John D., primary, Usmani, Saad Z., primary, van Rhee, Frits, primary, Anaissie, Elias, primary, Nair, Bijay, primary, Waheed, Sarah, primary, Alsayed, Yazan, primary, Petty, Nathan, primary, Bailey, Clyde, primary, Epstein, Joshua, primary, Hoering, Antje, primary, Crowley, John, primary, and Barlogie, Bart, primary

Published
2023
Full Text
View/download PDF

6. Supplementary Figure Legend from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1

Author

Heuck, Christoph J., primary, Szymonifka, Jackie, primary, Hansen, Emily, primary, Shaughnessy, John D., primary, Usmani, Saad Z., primary, van Rhee, Frits, primary, Anaissie, Elias, primary, Nair, Bijay, primary, Waheed, Sarah, primary, Alsayed, Yazan, primary, Petty, Nathan, primary, Bailey, Clyde, primary, Epstein, Joshua, primary, Hoering, Antje, primary, Crowley, John, primary, and Barlogie, Bart, primary

Published
2023
Full Text
View/download PDF

7. Supplementary Figure 4 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1

Author

Heuck, Christoph J., primary, Szymonifka, Jackie, primary, Hansen, Emily, primary, Shaughnessy, John D., primary, Usmani, Saad Z., primary, van Rhee, Frits, primary, Anaissie, Elias, primary, Nair, Bijay, primary, Waheed, Sarah, primary, Alsayed, Yazan, primary, Petty, Nathan, primary, Bailey, Clyde, primary, Epstein, Joshua, primary, Hoering, Antje, primary, Crowley, John, primary, and Barlogie, Bart, primary

Published
2023
Full Text
View/download PDF

8. Supplementary Figure 5 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1

Author

Heuck, Christoph J., primary, Szymonifka, Jackie, primary, Hansen, Emily, primary, Shaughnessy, John D., primary, Usmani, Saad Z., primary, van Rhee, Frits, primary, Anaissie, Elias, primary, Nair, Bijay, primary, Waheed, Sarah, primary, Alsayed, Yazan, primary, Petty, Nathan, primary, Bailey, Clyde, primary, Epstein, Joshua, primary, Hoering, Antje, primary, Crowley, John, primary, and Barlogie, Bart, primary

Published
2023
Full Text
View/download PDF

11. Spatial environmental factors predict cardiovascular and all-cause mortality: Results of the SPACE study

Author

Hadley, Michael B., primary, Nalini, Mahdi, additional, Adhikari, Samrachana, additional, Szymonifka, Jackie, additional, Etemadi, Arash, additional, Kamangar, Farin, additional, Khoshnia, Masoud, additional, McChane, Tyler, additional, Pourshams, Akram, additional, Poustchi, Hossein, additional, Sepanlou, Sadaf G., additional, Abnet, Christian, additional, Freedman, Neal D., additional, Boffetta, Paolo, additional, Malekzadeh, Reza, additional, and Vedanthan, Rajesh, additional

Published
2022
Full Text
View/download PDF

12. Hospital readmission in systemic sclerosis associated pulmonary hypertension: Results from the PHAROS registry.

Author

Showalter, Kimberly, Pinheiro, Laura C, Jannat-Khah, Deanna, Sobol, Irina, Szymonifka, Jackie, Finik, Jackie, Steen, Virginia D, and Gordon, Jessica K

Subjects
PULMONARY hypertension treatment, REPORTING of diseases, KRUSKAL-Wallis Test, CONFIDENCE intervals, PULMONARY hypertension, HOME care services, SYSTEMIC scleroderma, PATIENT readmissions, FISHER exact test, MANN Whitney U Test, RISK assessment, SEVERITY of illness index, COMPARATIVE studies, DESCRIPTIVE statistics, OXYGEN therapy, LOGISTIC regression analysis, ODDS ratio, DISEASE complications
Abstract

Objective To identify individual-level factors associated with hospital readmission among individuals with SSc-associated pulmonary hypertension (SSc-PH). Methods Individuals enrolled in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) registry contributed clinical data related to SSc-PH disease severity and hospital admissions. Readmission was defined as a subsequent hospitalization within 12 months of any hospital discharge. Characteristics were compared between individuals with and without readmissions using Fisher's exact test, Wilcoxon rank-sum test, or Kruskal–Wallis test. Logistic regression was used to estimate associations between clinical predictors and likelihood of readmission. Results Of 572 individuals with SSc-PH enrolled in PHAROS, 54% had ≥1 hospitalizations between 2005 and 2016. Among individuals ever-hospitalized, 34% had ≥1 readmission. Individuals with vs without readmissions had shorter median (IQR) time between index hospitalization date and next PHAROS visit [37 (3, 80) vs 81 (42, 136) days, P <0.001]. Index admissions related to PH or SSc (vs non-PH/SSc related) were associated with an increased odds of 12-month readmission [aOR 6.6 (95% CI 3.2, 13.6) and aOR 2.2 (95% CI 1.1, 4.5), respectively]. Readmission was less likely among home oxygen users (vs non-users) (aOR 0.44; 95% CI 0.22, 0.89). Race, age, sex, disease duration and disease subtype were not associated with readmission. Conclusion The strongest predictor for 12-month readmission was an index hospitalization reason related to PH. Home oxygen use was associated with lower odds of readmission. Future studies should determine whether testing for the need for home oxygen mediates the risk of readmission in SSc-PH. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results